ImmuCell Net Income
| ICCC Stock | USD 6.63 0.01 0.15% |
As of the 10th of February, ImmuCell retains the Market Risk Adjusted Performance of 0.1154, risk adjusted performance of 0.0506, and Downside Deviation of 3.8. ImmuCell technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
ImmuCell's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ImmuCell's valuation are provided below:ImmuCell does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Will Biotechnology sector continue expanding? Could ImmuCell diversify its offerings? Factors like these will boost the valuation of ImmuCell. Market participants price ImmuCell higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ImmuCell data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding ImmuCell requires distinguishing between market price and book value, where the latter reflects ImmuCell's accounting equity. The concept of intrinsic value - what ImmuCell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ImmuCell's price substantially above or below its fundamental value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, ImmuCell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
ImmuCell 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ImmuCell's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ImmuCell.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in ImmuCell on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding ImmuCell or generate 0.0% return on investment in ImmuCell over 90 days. ImmuCell is related to or competes with Equillium, Cue Biopharma, OUTLOOK THERAPEUTICS, Coeptis Therapeutics, OS Therapies, NRX Pharmaceuticals, and Fortress Biotech. ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and... More
ImmuCell Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ImmuCell's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ImmuCell upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.8 | |||
| Information Ratio | 0.028 | |||
| Maximum Drawdown | 13.43 | |||
| Value At Risk | (5.18) | |||
| Potential Upside | 5.49 |
ImmuCell Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImmuCell's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ImmuCell's standard deviation. In reality, there are many statistical measures that can use ImmuCell historical prices to predict the future ImmuCell's volatility.| Risk Adjusted Performance | 0.0506 | |||
| Jensen Alpha | 0.0397 | |||
| Total Risk Alpha | (0.19) | |||
| Sortino Ratio | 0.0267 | |||
| Treynor Ratio | 0.1054 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ImmuCell's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ImmuCell February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0506 | |||
| Market Risk Adjusted Performance | 0.1154 | |||
| Mean Deviation | 2.72 | |||
| Semi Deviation | 3.71 | |||
| Downside Deviation | 3.8 | |||
| Coefficient Of Variation | 1868.82 | |||
| Standard Deviation | 3.63 | |||
| Variance | 13.15 | |||
| Information Ratio | 0.028 | |||
| Jensen Alpha | 0.0397 | |||
| Total Risk Alpha | (0.19) | |||
| Sortino Ratio | 0.0267 | |||
| Treynor Ratio | 0.1054 | |||
| Maximum Drawdown | 13.43 | |||
| Value At Risk | (5.18) | |||
| Potential Upside | 5.49 | |||
| Downside Variance | 14.44 | |||
| Semi Variance | 13.75 | |||
| Expected Short fall | (2.87) | |||
| Skewness | (0.49) | |||
| Kurtosis | 0.9128 |
ImmuCell Backtested Returns
At this point, ImmuCell is slightly risky. ImmuCell holds Efficiency (Sharpe) Ratio of 0.0535, which attests that the entity had a 0.0535 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for ImmuCell, which you can use to evaluate the volatility of the firm. Please check out ImmuCell's Risk Adjusted Performance of 0.0506, downside deviation of 3.8, and Market Risk Adjusted Performance of 0.1154 to validate if the risk estimate we provide is consistent with the expected return of 0.19%. ImmuCell has a performance score of 4 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 1.75, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ImmuCell will likely underperform. ImmuCell right now retains a risk of 3.63%. Please check out ImmuCell maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside , to decide if ImmuCell will be following its current trending patterns.
Auto-correlation | -0.45 |
Modest reverse predictability
ImmuCell has modest reverse predictability. Overlapping area represents the amount of predictability between ImmuCell time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ImmuCell price movement. The serial correlation of -0.45 indicates that just about 45.0% of current ImmuCell price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.45 | |
| Spearman Rank Test | -0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 0.07 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, ImmuCell reported net income of (2.16 Million). This is 100.63% lower than that of the Biotechnology sector and 103.08% lower than that of the Health Care industry. The net income for all United States stocks is 100.38% higher than that of the company.
ImmuCell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmuCell's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmuCell could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics of similar companies.ImmuCell is currently under evaluation in net income category among its peers.
ImmuCell Fundamentals
| Return On Equity | 0.0661 | ||||
| Return On Asset | 0.0302 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 69.78 M | ||||
| Shares Outstanding | 9.05 M | ||||
| Shares Owned By Insiders | 27.88 % | ||||
| Shares Owned By Institutions | 19.95 % | ||||
| Number Of Shares Shorted | 10.92 K | ||||
| Price To Earning | 195.00 X | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 2.16 X | ||||
| Revenue | 26.49 M | ||||
| Gross Profit | 10.99 M | ||||
| EBITDA | 1.07 M | ||||
| Net Income | (2.16 M) | ||||
| Cash And Equivalents | 11.04 M | ||||
| Cash Per Share | 1.43 X | ||||
| Total Debt | 15.1 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 6.91 X | ||||
| Book Value Per Share | 3.30 X | ||||
| Cash Flow From Operations | 357.9 K | ||||
| Short Ratio | 0.24 X | ||||
| Earnings Per Share | 0.21 X | ||||
| Target Price | 14.0 | ||||
| Number Of Employees | 77 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 54.73 M | ||||
| Total Asset | 45.1 M | ||||
| Retained Earnings | (14.16 M) | ||||
| Working Capital | 10.63 M | ||||
| Current Asset | 4.49 M | ||||
| Current Liabilities | 258.78 K | ||||
| Net Asset | 45.1 M |
About ImmuCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmuCell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuCell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Will Biotechnology sector continue expanding? Could ImmuCell diversify its offerings? Factors like these will boost the valuation of ImmuCell. Market participants price ImmuCell higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ImmuCell data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding ImmuCell requires distinguishing between market price and book value, where the latter reflects ImmuCell's accounting equity. The concept of intrinsic value - what ImmuCell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ImmuCell's price substantially above or below its fundamental value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, ImmuCell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.